The methylcobalamin tablets of Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Shanghai Xinya Pharmaceutical Minhang, passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's filing on the Shanghai Stock Exchange.
The pharmaceutical company spent 4 million yuan for the research and development, and the consistency evaluation of the drug, which is mainly used for peripheral neuropathy, the Tuesday filing noted.
Shares of the company rose less than 2% on the Hong Kong bourse.
Price (HKD): $18.87, Change: $-0.11, Percent Change: -0.58%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments